TEST:

Aristotle®

We accurately modelled acute diarrhea (AUC = 0.90) for rectal cancer patients receiving CRT using AI-contoured small-bowel structures. The treatment arm and small-bowel dose were independently correlated to the diarrhea severity. The explainable model allowed us to quantify the impact of radiation dose, usage of irinotecan, and its combination, with a threshold of V = 160.93 cm yielding an equivalent impact. We will be extending the analysis to the whole trial cohort to improve the statistical power.

These tests enable differentiation of BC from non-BC subjects (Syantra DX, BCtect), detection of small tumours <10 mm (early BC detection) (Syantra DX), detection of different cancers (including BC) from a single blood sample (multi-cancer blood test Aristotle), detection of BC in premenopausal and postmenopausal women and those with high breast density (Syantra DX), and improvement of diagnostic outcomes of DNA testing (variant interpretation) (+RNAinsight). The review also evaluates ongoing transcriptomic research on exciting possibilities for future assays, including blood transcriptome analyses aimed at differentiating lymph node positive and negative BC, distinguishing BC and benign breast disease, detecting ductal carcinoma in situ, and improving early detection further (expression changes can be detected in blood up to eight years before diagnosing BC using conventional approaches, while future metastatic and non-metastatic BC can be distinguished two years before BC diagnosis).

"StageZero Life Sciences, Ltd...announced that it has partnered with DiagnoseAtHome...to make the Company's multi-cancer blood test, Aristotle®, available to DiagnoseAtHome's patients in Canada and the USA. Built on StageZero's proprietary mRNA gene expression technology platform, Aristotle is a next-generation test which simultaneously screens for multiple cancers from a single sample of blood."